A Study of ANAVEX3-71 in Adults With Schizophrenia

Phase 2Active Not RecruitingNCT06245213

Anavex Life Sciences Corp.71 enrolled

Overview

A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.

ANAVEX3-71-SZ-001 is a two-part study. The first part is Part A: Multiple Ascending Dose, PK, safety, and dose selection. The second part is Part B: Double Blind, Placebo Controlled for exploratory efficacy and continued repeat-dose safety. This study will investigate the effects of ANAVEX3-71 in patients with Schizophrenia for the first time. This is an in-patient study. In both parts, participants will undergo either 10 or 28 days of dosing (Part A and Part B, respectively). Standard clinical outcome measures used in the clinic and novel fluid and electrophysiological biomarkers will also be assessed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Schizophrenia

Interventions

ANAVEX3-71 oral capsulesDRUG

ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.

Placebo oral capsulesDRUG

The placebo comparator for the study.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male and female volunteers 18-55 years of age, inclusive at screening. 2. Has a primary diagnosis of schizophrenia, for ≥ 1 year 3. Stable schizophrenia psychiatric symptoms for at least 6 weeks prior to screening. 4. Schizophrenia clinical symptom severity defined by meeting ALL of the following per the Positive and Negative Syndrome Scale (PANSS) item scores at screening: 1. Delusions (P1) ≤ 4 2. Hallucinatory behavior (P3) ≤ 4 3. Unusual thought content (G9) ≤ 4 4. Hostility (P7) ≤ 4 5. Patient has a PANSS total score ≤ 80 at screening and baseline visits and no worsening in PANSS total score between screening and baseline, of more than 20%. 6. Has a Brief Assessment of Cognition (BACS) T-score \< 50 at the screening visit. 7. On a stable regimen of at least one and up to a maximum of two second-generation ("atypical") antipsychotic medications for at least 6 weeks prior to screening and agree to stay on this regimen for their entire study participation, with the following exceptions: 1. Clozapine use is not permitted 2. Quetiapine for sleep at doses less than 300 mg are permitted. 3. Day time (including morning) quetiapine use as the background antipsychotic is not permitted. 8. Able to understand the requirements of the study and able and willing to provide written informed consent and to abide by the study procedures, in the judgment of the Investigator, including able and willing to remain in an in-patient setting during the study. 9. If of childbearing potential, using adequate contraceptive methods for the duration of the study. 10. Body mass index of 18.5 to 40.0 kg/m2 (inclusive) and total body weight \> 50 kg (110 lbs.) for males and \> 40 kg (88 lbs.) for females. 11. Has a negative urine screen for drugs of abuse and negative alcohol breath test at screening and check-in. 12. Patient resides in a stable living situation and is anticipated to return to that same stable living situation. Exclusion Criteria: 1. Participation in a schizophrenia study in which the patient has received any investigational medications within 60 days prior to the baseline visit. 2. History or presence of a clinically significant, poorly treated, or unstable conditions that would jeopardize the safety of the patient or the validity of the study results. 3. Clinically significant abnormal findings on the physical examination, medical history, ECG, or clinical laboratory results at screening. 4. Calgary Depression Scale for schizophrenia (CDSS) score ≥6 at the screening or baseline visits. 5. Simpson Angus Scale (SAS) total score ≥5 at the screening and baseline visits at the screening or baseline visits. 6. Abnormal Involuntary Movement (AIMS) score of 2 for two or more movements or a score of 3 or 4 for any single movement on this scale at the screening or baseline visits. 7. Any primary the DSM-5-TR (American Psychiatric Association 2022) disorder other than schizophrenia within 12 months before screening (confirmed using MINI version 7.0.2 at screening). 8. Pregnant, lactating, or less than 3 months postpartum. Sperm donation is not allowed for 90 days after the final dose of study drug. 9. Risk for suicidal behavior during the study. 10. Inability to detect a 1000 Hz tone at 40 dB in both ears at screening. 11. Has psychiatric hospitalization(s) for more than 30 days (cumulative) during the 90 days before screening.

Locations (1)

CenExel Hassman Research Institute

Marlton, New Jersey, United States

Outcomes

Primary Outcomes

Single Dose Maximum Observed Plasma Concentration (Cmax)

Pharmacokinetic blood measurements of ANAVEX3-71 and metabolite M8 at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose.

Time frame: Part A: Day 1

Multiple Dose Maximum Observed Plasma Concentration (Cmax)

Pharmacokinetic blood measurements of ANAVEX3-71 and metabolite M8 at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose.

Time frame: Part A: Day 1 and Day 9

Cmax (steady state)

The maximum plasma concentration of ANAVEX3-71 and metabolite M8 after reaching a steady state. With measurements taken at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose on Days 1 and 9.

Time frame: Part A: Day 1 and Day 9

Tmax (steady state)

The time to maximum plasma concentration of ANAVEX3-71 and metabolite M8 after reaching a steady state. With measurements taken at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose on Days 1 and 9.

Time frame: Part A: Day 1 and Day 9

AUC (steady state)

The area under the curve of the plasma concentration of ANAVEX3-71 and metabolite M8 after reaching a steady state. With measurements taken at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose on Days 1 and 9.

Time frame: Part A: Day 1 and Day 9

AUC (single state)

The area under the curve of the plasma concentration of ANAVEX3-71 and metabolite M8 after a single day of dosing. With measurements taken at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose on Days 1 and 9.

Time frame: Part A: Day 1 and Day 9

CL/F (steady state)

The oral clearance of ANAVEX3-71 and metabolite M8 after reaching a steady state. With measurements taken at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose on Days 1 and 9.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Time frame: Part A: Day 1 and Day 9

Vz/F (steady state)

The volume of distribution based on the terminal elimination phase following administration ANAVEX3-71 and metabolite M8 after reaching a steady state. With measurements taken at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose on Days 1 and 9.

Time frame: Part A: Day 1 and Day 9

T1/2 (steady state)

The time to elimination of half the quantity of ANAVEX3-71 and metabolite M8 after reaching a steady state. With measurements taken at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose on Days 1 and 9.

Time frame: Part A: Day 1 and Day 9

Rac (steady state)

The observed accumulation rate of ANAVEX3-71 and metabolite M8 after reaching a steady state. With measurements taken at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose on Days 1 and 9.

Time frame: Part A: Day 1 and Day 9

Rac, Cmax (steady state)

The observed accumulation ratio for Cmax of ANAVEX3-71 and metabolite M8 after reaching a steady state. With measurements taken at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose on Days 1 and 9.

Time frame: Part A: Day 1 and Day 9

PTR (steady state)

The peak-to-trough ratio at steady state for ANAVEX3-71 and metabolite M8 after reaching a steady state. With measurements taken at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose on Days 1 and 9.

Time frame: Part A: Day 1 and Day 9

Adverse Events

Safety as measured by the number of participants with treatment-related adverse events and the number of treatment-related adverse events, as assessed by CTCAE v4.0.